(ALDX) Aldeyra The - Ratings and Ratios
Reproxalap, ADX-2191, ADX-629, RASP Modulator, Immune Therapies
ALDX EPS (Earnings per Share)
ALDX Revenue
Description: ALDX Aldeyra The
Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing therapies for immune-mediated and metabolic diseases, with a pipeline of promising candidates, including reproxalap, ADX-2191, and ADX-629, targeting various indications such as dry eye disease, allergic conjunctivitis, retinitis pigmentosa, COVID-19, atopic asthma, psoriasis, and alcohol intoxication.
From a trading perspective, Aldeyras stock (ALDX) has shown significant volatility, with a 52-week high of $6.98 and a low of $1.42, and a current price of $4.65, indicating a potential for growth. The stocks short-term and long-term moving averages (SMA20: $3.72, SMA50: $2.90, SMA200: $4.56) suggest a bullish trend, with the short-term averages above the long-term average, indicating a potential buy signal.
To further evaluate Aldeyras potential, we can examine key performance indicators (KPIs) such as revenue growth, R&D expenses as a percentage of revenue, and cash burn rate. Although the companys P/E ratio is not available due to negative earnings, its market capitalization stands at $231.80M USD. The return on equity (RoE) is -72.58, indicating significant losses. Investors should closely monitor the companys cash reserves, burn rate, and upcoming milestones, such as the completion of Phase III clinical trials for reproxalap, to assess the potential for future growth.
Additionally, Aldeyras RASP platform, which includes several preclinical candidates, demonstrates the companys commitment to innovation and potential for future growth. The development of ADX-629, an orally administered RASP modulator, for multiple indications, including COVID-19, atopic asthma, and psoriasis, further expands the companys pipeline and potential market opportunities.
ALDX Stock Overview
| Market Cap in USD | 342m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2014-05-02 |
ALDX Stock Ratings
| Growth Rating | -23.7% |
| Fundamental | 26.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -28.5% |
| Analyst Rating | 4.71 of 5 |
ALDX Dividends
Currently no dividends paidALDX Growth Ratios
| Growth Correlation 3m | 77.3% |
| Growth Correlation 12m | -18.6% |
| Growth Correlation 5y | -55.2% |
| CAGR 5y | -5.52% |
| CAGR/Max DD 3y | -0.06 |
| CAGR/Mean DD 3y | -0.10 |
| Sharpe Ratio 12m | 0.68 |
| Alpha | 0.10 |
| Beta | 0.841 |
| Volatility | 73.59% |
| Current Volume | 846.5k |
| Average Volume 20d | 734.9k |
| Stop Loss | 4.5 (-8.2%) |
| Signal | -0.79 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-50.6m TTM) > 0 and > 6% of Revenue (6% = 14.7k TTM) |
| FCFTA -0.51 (>2.0%) and ΔFCFTA -26.80pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 22.5k% (prev 25.0k%; Δ -2471 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.48 (>3.0%) and CFO -41.0m > Net Income -50.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (60.0m) change vs 12m ago 1.06% (target <= -2.0% for YES) |
| Gross Margin -26.14% (prev 35.37%; Δ -61.51pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.23% (prev 0.31%; Δ -0.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -25.58 (EBITDA TTM -48.5m / Interest Expense TTM 1.90m) >= 6 (WARN >= 3) |
Altman Z'' -33.50
| (A) 0.65 = (Total Current Assets 84.6m - Total Current Liabilities 29.5m) / Total Assets 85.0m |
| (B) -5.53 = Retained Earnings (Balance) -469.8m / Total Assets 85.0m |
| warn (B) unusual magnitude: -5.53 — check mapping/units |
| (C) -0.46 = EBIT TTM -48.7m / Avg Total Assets 105.5m |
| (D) -15.83 = Book Value of Equity -469.8m / Total Liabilities 29.7m |
| Total Rating: -33.50 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.89
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -15.66% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.28 = 2.46 |
| 5. Debt/Ebitda -0.32 = -2.50 |
| 6. ROIC - WACC (= -66.89)% = -12.50 |
| 7. RoE -73.63% = -2.50 |
| 8. Rev. Trend 13.19% = 0.99 |
| 9. EPS Trend 8.75% = 0.44 |
What is the price of ALDX shares?
Over the past week, the price has changed by -11.55%, over one month by -9.93%, over three months by +58.58% and over the past year by -15.22%.
Is Aldeyra The a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALDX is around 4.77 USD . This means that ALDX is currently overvalued and has a potential downside of -2.65%.
Is ALDX a buy, sell or hold?
- Strong Buy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ALDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.5 | 93.9% |
| Analysts Target Price | 9.5 | 93.9% |
| ValueRay Target Price | 5.3 | 8.8% |
Last update: 2025-09-10 02:43
ALDX Fundamental Data Overview
CCE Cash And Equivalents = 81.9m USD (Cash And Short Term Investments, last quarter)
P/B = 6.1905
Beta = 0.789
Revenue TTM = 244.5k USD
EBIT TTM = -48.7m USD
EBITDA TTM = -48.5m USD
Long Term Debt = 143.4k USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 15.4m USD (from shortTermDebt, last quarter)
Debt = 15.6m USD (Calculated: Short Term 15.4m + Long Term 143.4k)
Net Debt = -25.7m USD (from netDebt column, last quarter)
Enterprise Value = 275.9m USD (342.3m + Debt 15.6m - CCE 81.9m)
Interest Coverage Ratio = -25.58 (Ebit TTM -48.7m / Interest Expense TTM 1.90m)
FCF Yield = -15.66% (FCF TTM -43.2m / Enterprise Value 275.9m)
FCF Margin = -17.7k% (FCF TTM -43.2m / Revenue TTM 244.5k)
Net Margin = -20.7k% (Net Income TTM -50.6m / Revenue TTM 244.5k)
Gross Margin = -26.14% ((Revenue TTM 244.5k - Cost of Revenue TTM 308.4k) / Revenue TTM)
Tobins Q-Ratio = -0.59 (set to none) (Enterprise Value 275.9m / Book Value Of Equity -469.8m)
Interest Expense / Debt = 3.03% (Interest Expense 470.6k / Debt 15.6m)
Taxrate = 21.0% (US default)
NOPAT = -48.7m (EBIT -48.7m, no tax applied on loss)
Current Ratio = 2.86 (Total Current Assets 84.6m / Total Current Liabilities 29.5m)
Debt / Equity = 0.28 (Debt 15.6m / last Quarter total Stockholder Equity 55.3m)
Debt / EBITDA = -0.32 (Net Debt -25.7m / EBITDA -48.5m)
Debt / FCF = -0.36 (Debt 15.6m / FCF TTM -43.2m)
Total Stockholder Equity = 68.7m (last 4 quarters mean)
RoA = -59.58% (Net Income -50.6m, Total Assets 85.0m )
RoE = -73.63% (Net Income TTM -50.6m / Total Stockholder Equity 68.7m)
RoCE = -70.71% (Ebit -48.7m / (Equity 68.7m + L.T.Debt 143.4k))
RoIC = -58.07% (NOPAT -48.7m / Invested Capital 83.9m)
WACC = 8.82% (E(342.3m)/V(357.8m) * Re(9.11%)) + (D(15.6m)/V(357.8m) * Rd(3.03%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 95.40 | Cagr: 0.24%
Discount Rate = 9.11% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -43.2m)
EPS Correlation: 8.75 | EPS CAGR: 45.76% | SUE: 0.87 | # QB: 1
Revenue Correlation: 13.19 | Revenue CAGR: 0.0% | SUE: N/A | # QB: None
Additional Sources for ALDX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle